![22411298](https://user-images.githubusercontent.com/22411298/83512337-b17a2d00-a4ed-11ea-85c8-ef890e47a826.png)
## Atanu Bhattacharjee,Ph.D (Statistics)
Assistant Professor Biostatistics
Centre for Cancer Epidemiology, Tata Memorial Centre, India
## Biography
I am working as Assistant Professor Biostatistics in the Section of Biostatistics, Centre for Cancer Epidemiology, Tata Memorial Centre, Mumbai.I am also an Ajunct Professor of Statistics at Department of Applied Mathematics, Indian Institute of Technology-Dhanbad. I completed by Ph.D in statistics under the supervision of Dr. Dilip C Nath.
My research interests include Bayesian inference, longitudinal data analysis, survival analysis, gene expression data analysis.
## Book Publication
1.Atanu Bhattacharjee (2021).Bayesian Approaches in Oncology Using R and OpenBUGS.(In press).CRC press.
2. Atanu Bhattacharjee (2013).Bayesian Analysis in Longitudinal Data. Lambert Publication.
### Chapters in Book
Gaurav Roy, Atanu Bhattacharjee, and Iqra Khan (2020).‘Essentials of Cancer Genomic,
Computational Approaches and Precision Medicine. Spinger Verlag, Nature.
## Research Paper
### [2020]
1.Nimisha Tripathi, Sneha Keshari, Pallavi Shahi, Poonam Maurya, Atanu Bhattacharjee, Kushal Gupta, Sanjay Talole, Mekesh Kumar.Human papillomavirus elevated genetic biomarker signature by statistical algorithm.Journal of Cellular Physiology(In press).

2.Abin Thomas,Gajendra K.Vishwakarma and Atanu Bhattacharjee.Joint modeling of longitudinal and time-to-event data on multivariate protein biomarkers.https://doi.org/10.1016/j.cam.2020.113016.

3.Atanu Bhattacharjee,Subita Patil,Sanjay Talole,Arjun Singh,Pankaj Chaturvedie,Rajesh Dikshit.An impact of single prevalence rate reduction of tobacco on cancer incidence- A challenge for global policy maker.https://doi.org/10.1016/j.cegh.2020.04.029.[pagination_CEGH_583.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4714852/pagination_CEGH_583.pdf).

4.Vijay M. Patil  Arti Bhelekar  Nandini Menon  Atanu Bhattacharjee  Vijai Simha  Ram Abhinav  Anuja Abhyankar  Epari Sridhar  Abhishek Mahajan  Ameya D. Puranik. Reverse swing‐M, phase 1 study of repurposing mebendazole in recurrent high‐grade glioma.cancer Medicine.https://doi.org/10.1002/cam4.3094.[2020I.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716315/2020I.pdf)


5.Atanu Bhattacharjee, Vijay M Patil, Rajesh Dikshit, Kumar Prabhash, Arjun Singh, Pankaj Chaturvedi.Should we wait or not? The preferable option for patients with stage IV oral cancer in COVID-19 pandemic.Head Neck
.2020 Jun;42(6):1173-1178. doi: 10.1002/hed.26196. Epub 2020 Apr 28.[2020G.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716313/2020G.pdf)


6.Atanu Bhattacharjee, Jacinth Rajendra, Rajesh Dikshit, Shilpee Dutt.HER2 borderline is a negative prognostic factor for primary malignant breast cancer.Breast Cancer Res Treat. 2020 May;181(1):225-231. doi: 10.1007/s10549-020-05608-3.[2020F.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716308/2020F.pdf)

7.Atanu Bhattacharjee.Bayesian competing risks analysis without data stratification.DOI:https://doi.org/10.1016/j.cegh.2019.08.010.[2020E.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716303/2020E.pdf)

8.Akshat Malik,Sudhir Nair,Arjun Singh,Komal Lamba,Swapnil Rane,Munita Bal,Atanu Bhattacharjee,Hisham Mehanna, Pankaj Chaturvedi.Soft tissue deposit in neck dissection specimen carries a poor prognosis in oral cancer: A matched pair analysis.https://doi.org/10.1002/hed.26103. [2020A.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716274/2020A.pdf)

9.Vanita Noronha,Vijay Maruti Patil,Amit Joshi,Manoj Mahimkar,Usha Patel,Manish Kumar Pandey,Arun Chandrasekharan,Hollis Dsouza,Atanu Bhattacharjee,Abhishek Mahajan,Nilesh Sabale,Jai Prakash Agarwal,Sarbani Ghosh-Laskar,Ashwini Budrukkar,Anil K D'Cruz,Pankaj Chaturvedi ,Prathamesh S Pai,Devendra Chaukar, Sudhir Nair,Shivakumar Thiagarajan,Shripad Banavali,Kumar Prabhash.
Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer. Oncotarget
. 2020 Jan 28;11(4):399-408. doi: 10.18632/oncotarget.27443.[2020B.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716284/2020B.pdf)

10.Vanita Noronha,Atanu Bhattacharjee,Vijay M Patil,Amit Joshi,Nandini Menon,Srushti Shah,Sadhana Kannan,Sadaf A Mukadam, Kamesh Maske, Sandeep Ishi, Kumar Prabhash.Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial.Chest
. 2020 Jan 18;S0012-3692(20)30032-5. doi: 10.1016/j.chest.2019.11.048.[2020C.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4729558/2020C.pdf)


11.Vijay Maruti Patil,Vanita Noronha,Shivakumar Thiagarajan,Amit Joshi,Arun Chandrasekharan,Vikas Talreja,Jaiprakash Agarwal,Sarbani Ghosh-Laskar,Ashwini Budrukkar,Shashikant Juvekar,Abhishek Mahajan,Archi Agarwal,Nilendu Purandare,Atanu Bhattacharjee, Anil K D'Cruz, Pankaj Chaturvedi,Prathamesh S Pai 2,Devendra Chaukar,Kumar Prabhash.Salvage surgery in head and neck cancer: Does it improve outcomes?Eur J Surg Oncol. 2020 Jan 15;S0748-7983(20)30024-X. doi: 10.1016/j.ejso.2020.01.019.[2020D.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716296/2020D.pdf)

## [2019]
1. Amit Joshi, Sameer Shrirangwar, Vanita Noronha, Nilesh Sable, Archi Agarwal, Palak Popat, Atanu Bhattacharjee, Kumar Prabhash.
 A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer.South Asian J
Cancer 2020;9:23-6.
2. Thiagarajan S, Dhar H, Bhattacharjee A, Fatehi KS, Shah SB, Chaukar D, Nair D, Deshmukh A, Prabhash K, Joshi A, Patil V, Noronha V, Laskar SG, Cruz AKD.Patterns of failure and outcomes in cT4 Oral squamous cell carcinoma (OSCC) undergoing upfront surgery in comparison to Neo-Adjuvant Chemotherapy (NACT) followed by surgery: A Matched Pair analysis.Oral Oncol. 2019 Nov 15;100:104455. doi: 10.1016/j.oraloncology.2019.104455.
3. Narasimhan M, Kannan S, Chawade A, Bhattacharjee A, Govekar R. Clinical biomarker discovery by SWATH-MS based label-free quantitative proteomics: impact of criteria for identification of differentiators and data normalization method.J Transl Med. 2019 May 31;17(1):184. doi: 10.1186/s12967-019-1937-9.
4. Patil V#1,2, Joshi A#1,2, Noronha V1,2, Agarwala V1,2, Chougule A1,2, Kanan S, Bhattacharjee A, Chandrasekharan A, Pande N, Simha V, Goud S, More S, Kumar R, Mahajan A, Janu A, Purandare N, Prabhash K.Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer.Oncotarget. 2019 Oct 29;10(59):6297-6307. doi: 10.18632/oncotarget.27214. eCollection 2019 Oct 29.
5. Singhavi HR, Chakrabarti S, Singh A, Mair M, Bhattacharjee A, Shetty R, Qayyumi B, Pai A, Joshi P, Nair D, Nair S, Chaturvedi P.Comparison of the 7th and 8th edition AJCC classification system in oral cavity squamous cell cancers.Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32720. 
6. Vijay Patil, Vanita Noronha, Amit Joshi, Anuradha Chougule, Atanu Bhattacharjee, Alok Goel, Vikas Talreja, Nandini Menon, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash.
Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/ carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer.Cancer Research,Statistics and Treatment.2019 2(1).21-27.
7. Patil VM, Noronha V, Joshi A, Agarwal J, Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, Mahimkar M, Juvekar S, Arya S, Mahajan A, Agarwal A, Purandare N,Rangarajan V, Balaji A, Chaudhari SV, Banavali S, Kannan S, Bhattacharjee A, D'Cruz AK, Chaturvedi P, Pai PS, Chaukar D, Pantvaidya G, Nair D, Nair S, Deshmukh A,Thiagarajan S, Mathrudev V, Manjrekar A, Dhumal S, Maske K, Bhelekar AS, Nawale K, Chandrasekharan A, Pande N, Goel A, Talreja V, Simha V, Srinivas S, Swami R,Vallathol DH, Dsouza H, Shrirangwar S,Turkar S, Abraham G, Thanky AH,Patel U,Pandey MK,Prabhash K.A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.Cancer. 2019 Sep 15;125(18):3184-3197. doi: 10.1002/cncr.32179. Epub 2019 May 31.
8. Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, Goud S, Kadam N, Daware N, Bhattacharjee A, Shah S, Yadav A,
Trivedi V, Behel V, Dutt A, Banavali SD, Prabhash K.Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.J Clin Oncol. 2019 Aug 14:JCO1901154. doi: 10.1200/JCO.19.01154.
9. Bhattacharjee A.Bayesian competing risks analysis without data stratification.Clinical Epidemiology and Global Health (In press) 2019.
10.Mukesh Kumar  Prashant Kr. Sonker  Agni Saroj  Aanchal Jain  Atanu Bhattacharjee  Rakesh Kr. Saroj.
Cancer Reports.Parametric survival analysis using R: Illustration with lung cancer data.2019. https://doi.org/10.1002/cnr2.1210
11. Bhattacharjee A.A joint longitudinal and survival model for dynamic treatment regimes in Presence of Competing Risk Analysis.
Clinical Epidemiology and Global Health.2019.7(3).337-341.
12. Bhattacharjee A,Budukh A,Dikshit  R.Prostate cancer survival estimates: An application with piecewise hazard function derivation.South Asian journal of cancer.2019.8(3).105.
13. A Bhattacharjee, GK Vishwakarma.Time-course data prediction for repeatedly measured gene expression.International Journal of Biomathematics.2019.12(4).
14. Vijay M Patil, Arun Chandrasekharan, Dilip Harindran Vallathol, Mridul Malhotra, Ram Abhinav, Priti Agarwal, Anu Rajpurohit, Raees Tonse, Atanu Bhattacharjee, Rakesh Jalali. Antiemetic prophylaxis with temozolomide: an audit from a tertiary care center.2019.Neuro-Oncology Practice.4(19).
15. Atanu Bhattacharjee, Gaurav Roy, Atul Budukh, Rajesh Dikshit, Vijay M Patil, Amit Joshi, Vanita Noronha, Kumar Prabash, Papai Roy A competing risk analysis of death patterns in male genitourinary cancer.(2019).Cancer Reports, e1174.
## [2018]
 
1.Atanu Bhattacharjee,Gajendra K. Vishwakarma,Abin Thomas.Bayesian state-space modeling in gene expression data analysis: An
application with biomarker prediction.2018;Mathematical Biosciences.2018 Nov;305:96-101. doi: 10.1016/j.mbs.2018.08.011. Epub 2018 Sep 5.[2018A.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716508/2018A.pdf)

2.Vijay Patil, Amit Joshi, Vanita Noronha, Atanu Bhattacharjee1, Sachin Dhumal, M. V. Chandrakanth, Ashay Karpe,
Vikas Talreja, Arun Chandrasekharan, Siddharth Turkar, Nikhil Pande, Anant Ramaswamy, Kumar Prabhash. Quality of life and quality‑adjusted time without toxicity in palliatively treated
head‑and‑neck cancer patients.South Asian J Cancer
2018;7:249-53.[2018B.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716509/2018B.pdf).

3.Vanita Noronha,Avinash Pandey,Vijay Patil,Amit Joshi,Anuradha Bharat Choughule,Atanu Bhattacharjee,Rajiv Kumar,Supriya Goud,Sucheta More,Anant Ramaswamy,Ashay Karpe,Nikhil Pande, Arun Chandrasekharan,Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash.Tyrosine Kinase Inhibitor versus Physician Choice Chemotherapy in
Second‑Line Epidermal Growth Factor Receptor Mutation Non‑Small Cell
Lung Cancer: Post hoc Analysis of Randomized Control Trial.Indian Journal of Medical and Paediatric Oncology.2018;39(4).493-498.[2018C.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716510/2018C.pdf).

4.Biju Menon,Atanu Bhattacharjee,Sandip Basu.Comparison of Radioiodine uptake by Gamma Camera and
Thyroid uptake probe‐based methodologiesand Diagnostic
Radioiodine Scanin Differentiated thyroid carcinoma.J of Nuclear Medicine Technology, doi:10.2967/jnmt.118.207837.[2018D.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716512/2018D.pdf).

5.Vijay M. Patil, Mridul Malhotra, Raees Tonse, Jayita Deodhar, Arun Chandrasekharan,
Nikhil Pande, Atanu Bhattacharjee, and Rakesh Jalali.A cross-sectional audit of distress in patients
undergoing adjuvant therapy or follow-up in central
nervous system malignancies.Neuro-Oncology Practice.Neuro-Oncology Practice, Volume 6, Issue 4, August 2019, Pages 305–310, https://doi.org/10.1093/nop/npy046.[2018E.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716514/2018E.pdf).

6.Patil V, Joshi A, Noronha V, Dhumal S,
Chandrasekharan A, Pande N, et al. Quality of life without toxicity or
symptoms analysis of a randomized controlled clinical trial comparing
efficacy of cabazitaxel versus docetaxel in recurrent head and neck cancer.
Cancer Res Stat Treat 2018;1:46-50.[2018F.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716515/2018F.pdf).

7.Bhattacharjee A, Vishwakarma GK, Banerjee S.
A Bayesian approach for dynamic treatment regimes in the presence of
competing risk analysis. Cancer Res Stat Treat 2018;1:51-7.[2018G.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716516/2018G.pdf).

8.Influence of Hypothyroidism After Chemoradiation on Outcomes in
Head and Neck Cancer.Clinical Oncology xxx (2018) 1.[2018H.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716519/2018H.pdf).

9.Atanu Bhattacharjee,Vijay M. Patil,Vanita Noronha,Amit Joshi,Kumar Prabhash.An Algorithm to Define the Optimum Biological Dose
of Metronomic Chemotherapy.Biometrical Letters
Vol. 0 (2018), No. 0, xx-xx.[2018I.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716520/2018I.pdf).

10. Nair CK, Raghavan V, Bhattacharjee A, Kurup AR. Impact of early reduction in paraprotein on survival in transplant ineligible myeloma: Lesson from a tertiary cancer center in rural India.Amit Joshi, Vijay Patil, Vanita Noronha, Anuradha Chougule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash: Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?. Lung India 01/2018; 35(1):27., DOI:10.4103/lungindia.lungindia_201_17. [2018K.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716521/2018K.pdf)
## [2017]
## [2016-2014]
1.VM Patil,S Chakraborty,TK Jithin, S Dessai, TP Sajith Babu,V Raghavan, M Geetha, T Shiva Kumar, MS Biji, A Bhattacharjee, C Nair.Development and validation of a questionnaire to measure preferences and expectations of patients undergoing palliative chemotherapy: EXPECT questionnaire.Indian Journal of Cancer.2016;53(2),339-344.[2016A.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716367/2016A.pdf).

2.SB Dessai,VM Patil,S Chakraborty,S Babu,A Bhattacharjee,S Nayanar,S Vikram, S Balasubramanian.An audit of cytoreductive surgeries in ovarian cancer from a rural based cancer center.Indian Journal of Cancer.2016;53(2),284-287.[2016B.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716368/2016B.pdf).

3.VM Patil,S Chakraborty,TK Jithin,S Dessai,TP Sajith Babu,V Raghavan,M Geetha,T Shiva Kumar,MS Biji,A
Bhattacharjee, C Nair.Development and validation of a questionnaire to measure preferences and
expectations of patients undergoing palliative chemotherapy: EXPECT questionnaire.Indian Journal of Cancer.2016;53(2),339-344.[2016C.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716369/2016C.pdf).

4.Vijay M. Pati, Vanita Noronha, Amit Joshi, Saurabh Zanwar, Anant Ramaswamy, Supreeta Arya, Abhishek Mahajan,
Atanu Bhattacharjee, Kumar Prabhash.Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy
in head and neck cancers: Myth or reality?[2016D.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716370/2016D.pdf).

5.Atanu Bhattacharjee,Vijay M. Patil.Time-Dependent Area Under the ROC Curve
for Optimum Biological Dose Detection.Turkiye Klinikleri J Biostat 2016;8(2):103-9.[2016E.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716371/2016E.pdf).

6.SB Dessai, S Chakraborty, TVS Babu, S Nayanar, A Bhattacharjee,J Jones,S Balasubramanian,VM Patil,Tolerance of weekly paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced
ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin.Indian Journal of Cancer.2016;53(2),280-283.[2016F.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716372/2016F.pdf).

7.Vijay M. Patil,Vanita Noronha,Amit Joshi,Vamshi Muddu,Sachin Dhumal,Atanu Bhattacharjee,Kumar Prabhash.Compliance With Neoadjuvant
Chemotherapy in T4 Oral Cancers:Place, Person, Socioeconomic Status, or
Assistance(2015).JGO – Journal of Global Oncology.1(2).[2016G.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716373/2016G.pdf).

8.Vijay Patil,Amit Joshi, Vanita Noronha,Jayita Deodhar,Atanu Bhattacharjee,Sachin Dhumal,M.V.K. Chandrakanth,Ashay Karpe,Vikas Talreja,
Arun Chandrasekharan,Siddharth Turkar,Anant Ramaswamy,Kumar Prabhash.Oral Oncology 63 (2016) 10–15.Expectations and preferences for palliative chemotherapy in head and neck cancers patients[2016H.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716374/2016H.pdf).

9.Ramesh K. Vishwakarma,Dilip C. Nath,Atanu Bhattaharjee.Working Correlation Structures:Application in Liver Cirrhosis
Therapeutic Effect Trial.Turkiye Klinikleri J Biostat 2016;8(2):116-24.[2016I.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716375/2016I.pdf).

10.Dilip C. Nath, Ramesh K. Vishwakarma, Atanu Bhattacharjee.A selection modelling approach to analysing missing data
of liver Cirrhosis patients.Biometrical Letters
Vol. 53 (2016), No. 2, 83-103[2016J.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716378/2016J.pdf).

11.Niranjan Gopal,Bidhan Chandra Koner,Atanu Bhattacharjee, Vishnu Bhat.Assay of Urinary Protein-Bound Sialic Acid can Differentiate Steroid-Sensitive Nephrotic Syndrome from Steroid-Resistant Cases.Saudi J Kidney Dis Transpl 2016;27(1):37-40.[2016K.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4716379/2016K.pdf)

12.Efficacy of second-line erlotinib in patients postprogression of first-line chemotherapy in
head and neck cancers.2015;52(4).629-631.[2015A.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4715124/2015A.pdf)

13.S. Kane,V.M. Patily,A. Joshi,V. Noronha,V. Muddu,S. Dhumal,S. Juvekar,S. Arya,A. D’Cruz,A. Bhattacharjee,K. Prabhash.[2015B.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4715125/2015B.pdf)

14.Neoadjuvant Chemotherapy in Technically Unresectable Oral Cancers:
Does Human Papillomavirus Make a Difference?Clinical Oncology xxx (2015) 1e2.[2015C.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4715128/2015C.pdf)

15.Dilip C Nath,Atanu Bhattacharjee and Ramesh K Vishwakarma.The Cure Rate Modeling: An Application with Bayesian approach in Liver
Cirrhosis Patients.Journal of Data Science 13(2015), 421-442.[2015D.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4715129/2015D.pdf)

16.Atanu Bhattacharjee,and Tapesh Bhattacharyya.Bayesian Concordance Correlation Coefficient with Application to Repeatedly Measured Data.Turkiye Klinikleri J Biostat 2015;7(2):55-62 [2015E.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4715130/2015E.pdf).

17.Atanu Bhattacharjee and Santam Chakraborty."In regard to Livi et al. “Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5 year survival analysis of a phase 3 randomised controlled trial".European Journal of Cancer (2015) 51, 1476– 1477.[2015F.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4715132/2015F.pdf)

18.Atanu BhattacharjeeDistance Correlation Coefficient: An Application with Bayesian Approach in Clinical Data Analysis.Journal of Modern Applied Statistical Methods 2014;13(1):354-366.[2014A.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4715052/2014A.pdf)

19.Atanu Bhattacharjee, and Subhradev Sen.Letter to the editor: Second, third, and fourth head and neck tumors. A progressive
decrease in survival.Head & Neck 36: 1376, 2014.[2014B.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4715056/2014B.pdf)

20.Atanu Bhattacharjee and Dilip C. Nath.Joint Longitudinal and Survival Data Modeling: An Application inAnti-Diabetes Drug Therapeutic Effect. Statistics in Transition new series.2014;15(3).437-452.
[2014C.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4715058/2014C.pdf)

### [2013-2012]
21.Bhattacharjee Atanu,and  Saikia Hemanta.An Application of Bootstrap Regression Method in Age Dependency Structure to the Community.
Indian Journal of Public Health Research & Development.2013;4(3).44-48.[2013A.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4715108/2013A.pdf)

22.Bhattacharjee A, Bhattacharjee D. A Bayesian Approach to Compare the Statewise Dengue Death Counts in India. International Journal of Collaborative Research on Internal Medicine & Public Health. 2011; 3(10):715-723.[20200602100511.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4714786/20200602100511.pdf)

23.Dilip C. Nath and Atanu Bhattacharjee. Comparison of the tetrachoric correlation coefficients and odds in generalized estimating equation with Bayesian approach: an application in type 2 diabetes patients data.2011;5(2):97-108.
[20200602101224.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4714806/20200602101224.pdf).

24.Hemanta Saikia,Dibyojyoti Bhattacharjee,and Atanu Bhattacharjee.Is IPL responsible for cricketers’ performance in Twenty20 World Cup?
International Journal of Sports Science and Engineering.2012;6(02):096-110.[20200602102234.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4714831/20200602102234.pdf)

25.Dilip C. Nath and Atanu Bhattacharjee.Effect of Correlation Structure in Generalized Estimating Equation and Quasi Least Square: An Application in Type 2 Diabetes Patient. Pak.j.stat.oper.res.2011.VII(2).401-412.
[20200602102044.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4714821/20200602102044.pdf)

26.A Bayesian Approach for Autoregressive Models in Longitudinal Data Analysis: An Application to Type 2 Diabetes Drug Comparison.[20200602101832.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4714820/20200602101832.pdf)

### Biostatistics Tutorial
1. Introduction to Biostatistics
[1546938553M1.pdf](https://github.com/atanustat/biostatonco/files/4000779/1546938553M1.pdf)
2. Survival Analysis
[Survival Analysis.pdf](https://github.com/atanustat/biostatonco/files/4000798/Survival.Analysis.pdf)
3. Parametric survival analysis
[parametric survival analysis.pdf](https://github.com/atanustat/biostatonco/files/4000800/parametric.survival.analysis.pdf)
4. Acturial estimator with R
[Acturial estimator with R.pdf](https://github.com/atanustat/biostatonco/files/4000801/Acturial.estimator.with.R.pdf)
5. Kaplan Meier Estimators-I
[Kaplan Meier Estimators-I.pdf](https://github.com/atanustat/biostatonco/files/4000802/Kaplan.Meier.Estimators-I.pdf)
6. Kaplan Meier Estimators-II
[Uploading Kaplan Meier Estimators-Ii.pdf…]()
7. Nelson aalen estimator
[nelson aalen estimator.pdf](https://github.com/atanustat/biostatonco/files/4001281/nelson.aalen.estimator.pdf)
8. Equality of survival
[equality of survival function.pdf](https://github.com/atanustat/biostatonco/files/4001282/equality.of.survival.function.pdf)
9. Mantel Haenszel Estimator
[Mantel-Haenszl Estimators.pdf](https://github.com/atanustat/biostatonco/files/4001284/Mantel-Haenszl.Estimators.pdf)
10. Cox PH Model
[Cox PH model.pdf](https://github.com/atanustat/biostatonco/files/4001285/Cox.PH.model.pdf)

11. Estimation and Inference for Cox’s [Estimation and Inference for Cox’s.pdf](https://github.com/atanustat/biostatonco/files/4001298/Estimation.and.Inference.for.Cox.s.pdf)
12. Diagnostics for Cox’s PH model [Diagnostics for Cox’s PH model.pdf](https://github.com/atanustat/biostatonco/files/4001299/Diagnostics.for.Cox.s.PH.model.pdf)
13. The Accelerated Failure Time [The Accelerated Failure Time.pdf](https://github.com/atanustat/biostatonco/files/4001300/The.Accelerated.Failure.Time.pdf)
14. Competing Risks Model [Competing Risks Model.pdf](https://github.com/atanustat/biostatonco/files/4001301/Competing.Risks.Model.pdf)
15. Clinical Trials [Clinical Trials.pdf](https://github.com/atanustat/biostatonco/files/4001302/Clinical.Trials.pdf)
16. Sample size determination
[sample size determination.pdf](https://github.com/atanustat/biostatonco/files/4001312/sample.size.determination.pdf)
17. Random Allocation
[random allocation.pdf](https://github.com/atanustat/biostatonco/files/4001314/random.allocation.pdf)
18. Sequential Clinical Trial-I
[sequential clinical trial.pdf](https://github.com/atanustat/biostatonco/files/4001315/sequential.clinical.trial.pdf)
19. Sequential Clinical Trial-II
[sequential clinical trial II.pdf](https://github.com/atanustat/biostatonco/files/4001316/sequential.clinical.trial.II.pdf)
20. Sequential Clinical Trial-III
[sequential clinical trial III.pdf](https://github.com/atanustat/biostatonco/files/4001318/sequential.clinical.trial.III.pdf)
21. Randomize play the winder rule
[Randomize play the winder rule.pdf](https://github.com/atanustat/biostatonco/files/4001329/Randomize.play.the.winder.rule.pdf)
22. The Play the Winnder Rule [The Play the Winnder Rule.pdf](https://github.com/atanustat/biostatonco/files/4001331/The.Play.the.Winnder.Rule.pdf)
23. Crossover Trial[Crossover trial.pdf](https://github.com/atanustat/biostatonco/files/4001332/Crossover.trial.pdf)
24. Introduction to Epidemiology[Introduction to Epidemiology.pdf](https://github.com/atanustat/biostatonco/files/4001333/Introduction.to.Epidemiology.pdf)
25. Disease Frequency[Disease Frequency-I.pdf](https://github.com/atanustat/biostatonco/files/4001335/Disease.Frequency-I.pdf)
26. Disease Frequency-II[Disease Frequency-II.pdf](https://github.com/atanustat/biostatonco/files/4001354/Disease.Frequency-II.pdf)
27. Disease Frequency-III[Disease Frequency-III.pdf](https://github.com/atanustat/biostatonco/files/4001358/Disease.Frequency-III.pdf)
28. Observational Study[Observational Study.pdf](https://github.com/atanustat/biostatonco/files/4001360/Observational.Study.pdf)
29. Analystical Study[Analytical Study.pdf](https://github.com/atanustat/biostatonco/files/4001353/Analytical.Study.pdf)
30. Case Control Study[Case Control Study.pdf](https://github.com/atanustat/biostatonco/files/4001352/Case.Control.Study.pdf)
31. Cohort Study-I [Cohort Study -I.pdf](https://github.com/atanustat/biostatonco/files/4001350/Cohort.Study.-I.pdf)
32. Cohort Study-II [Cohort Study-II.pdf](https://github.com/atanustat/biostatonco/files/4001349/Cohort.Study-II.pdf)
33.  Case Control Study -I[case Control Study -I.pdf](https://github.com/atanustat/biostatonco/files/4001346/case.Control.Study.-I.pdf)
34.  Case Control Study -II[Case Control Study II.pdf](https://github.com/atanustat/biostatonco/files/4001343/Case.Control.Study.II.pdf)
35. Confounding[confounding.pdf](https://github.com/atanustat/biostatonco/files/4001342/confounding.pdf)
36. Stratified Analysis[Stratified Analysis.pdf](https://github.com/atanustat/biostatonco/files/4001340/Stratified.Analysis.pdf)
37. Matched Analysis-I[Matched Analysis-I.pdf](https://github.com/atanustat/biostatonco/files/4001337/Matched.Analysis-I.pdf)
38.  Matched Analysis-I[Mathced Analysis-II.pdf](https://github.com/atanustat/biostatonco/files/4001336/Mathced.Analysis-II.pdf)
39. Lung Cancer Update 2019 [presentation.pdf](https://github.com/atanustat/biostatonco/files/4002993/presentation.pdf).
40. Computational Biostatistics and Survival Analysis Talk[cce presentation.pdf](https://github.com/atanustat/biostatonco/files/4002995/cce.presentation.pdf).
41. Hands on Survival Analysis Researchers.(https://github.com/atanustat/biostatonco/files/4710190/AB1011.Hands.on.Survival.Analysis.pdf)
### Contact
abhattacharjee@actrec.gov.in/atanustat@gmail.com   
Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai,India


